Clinical trials
Melanoma clinical trials
A serious form of skin cancer that develops in pigment-producing cells. We’re tracking 458 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03842943RecruitingPhase 2
Before-surgery immunotherapy for stage III melanoma
This trial tests immunotherapy given before surgery to help shrink or control stage III melanoma that has spread to nearby areas (lymph nodes/region). If it works, it may improve outcomes after the melanoma is removed.
Louisville, KentuckyAges 18 years+ - NCT05649683Recruiting
Blood immune testing to predict melanoma response to immunotherapy
This study checks how your immune system behaves (through an immune testing process) to see if it can predict how well advanced melanoma will respond to checkpoint inhibitor treatment. It may help doctors choose the right treatment sooner, without guessing.
Nice, Alpes-maritimesAges 18 years+ - NCT07847359RecruitingPhase 2
Freezing and drug combination for melanoma that has spread to the liver
This trial tests a combination of treatments for melanoma that has spread to the liver after standard treatment. It uses freezing (cryoablation), a targeted drug (lenvatinib), chemotherapy (dacarbazine), and two immunotherapy drugs to try to shrink liver tumors and control the cancer. The goal is to see if this combined approach is safe and effective for patients whose cancer has not responded to prior therapy.
Guangzhou, GuangdongAges 18–75 - NCT06008106RecruitingPhase 3
Tunlametinib pill vs chemo for advanced NRAS melanoma
This trial tests a new pill called Tunlametinib (a MEK inhibitor) compared to standard chemotherapy for people with advanced melanoma that has a specific NRAS gene change and no longer responds to immunotherapy. It aims to see if the new pill works better or is safer than chemo.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07804186RecruitingPhase 3
Adjuvant therapy for high-risk uveal melanoma
This trial is testing a combination of two oral medications (darovasertib and crizotinib) after standard local treatment for high-risk uveal melanoma that has not spread. The goal is to see if this treatment can reduce the risk of the cancer coming back.
Scottsdale, ArizonaAges 18 years+ - NCT05478876Recruiting
Carbon ion radiation for vaginal or cervix mucosal melanoma
This trial studies whether carbon ion radiation can control mucosal melanoma in the lower female genital tract. It may help by targeting the tumor with high-precision radiation while trying to protect nearby organs like the bladder and rectum.
PaviaAges 20–80 - NCT07750067RecruitingPhase 2
Combination therapy for advanced melanoma with NRAS mutation
This trial tests a combination of three drugs (tunlametinib, pucotenlimab, and hydroxychloroquine) for people with advanced melanoma that has a specific genetic change called NRAS. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Guangzhou, GuangdongAges 18 years+ - NCT06602648Recruiting
Melanoma care study for young patients
This study aims to find better ways to treat melanoma in children, teenagers, and young adults. It may help improve care for patients under 30 years old with certain types of skin growths.
Florence, ItalyAges Up to 30 years - NCT06621810Recruiting
AI for melanoma detection in children and young adults
This study uses artificial intelligence to help detect melanoma (a type of skin cancer) and predict risk in children, teens, and young adults. Researchers want to see if AI can spot melanoma early and assess risk better.
TübingenAges Any age - NCT07718243RecruitingPhase 1/Phase 2
Combining two immunotherapies for solid tumors, melanoma, and lung cancer
This trial tests a new drug (bexmarilimab) plus nivolumab (an approved immunotherapy) for people with advanced solid tumors, melanoma, or non-small cell lung cancer (NSCLC) that has stopped responding to standard treatments.
ManchesterAges 18 years+ - NCT04605146Recruiting
Telemonitoring to manage side effects from immunotherapy
This trial tests whether using home digital monitoring (telemonitoring) can help people with melanoma, lung, or kidney (renal) cancer manage side effects while on immunotherapy. It may help catch side effects earlier and support you during treatment with nivolumab plus ipilimumab or nivolumab alone.
BronAges 18 years+ - NCT07704918Recruiting
Study: Lowering cholesterol during melanoma immunotherapy
This study tests whether giving aggressive cholesterol-lowering medication to people starting immunotherapy for melanoma can improve heart health. It may help reduce the risk of heart problems during cancer treatment.
Aurora, ColoradoAges 55 years+ - NCT05878977Recruiting
Testing biomarkers in immunotherapy for advanced melanoma
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
LjubljanaAges 18 years+ - NCT07691255Recruiting
Melanoma Brain Tumors Treated with CyberKnife
This trial tests CyberKnife, a precise radiation treatment, for melanoma that has spread to the brain. It may help you if you haven't had whole-brain radiation or brain surgery before.
Milan, ItalyAges 18 years+ - NCT07696715Recruiting
Timing of immunotherapy for melanoma
This trial studies the timing of a standard immunotherapy combination for advanced melanoma that cannot be removed by surgery or has spread. It aims to understand how timing affects treatment results.
AmsterdamAges 18 years+ - NCT06651151RecruitingPhase 2
Neoadjuvant LTX-315 plus pembrolizumab for resectable melanoma
This trial tests a combination of two drugs (LTX-315 and pembrolizumab) given before surgery to shrink melanoma that is stage III or IV (M1a) and can be removed. The goal is to see if this approach works better than surgery alone.
Oslo, OsloAges 18 years+ - NCT07680699Recruiting
Early immunotherapy for high-risk stage II melanoma
This trial tests early anti-PD-1 therapy for people with stage IIB or IIC melanoma, or stage III (N1c). It aims to see if starting treatment sooner helps prevent the cancer from coming back.
São Paulo, São PauloAges 18 years+ - NCT07680452Recruiting
High-fiber diet and short-term fasting for melanoma patients on immunotherapy
This trial tests if a high-fiber diet and occasional short-term fasting can help melanoma patients respond better to immunotherapy. It aims to improve treatment outcomes by changing gut health.
Berlin, State of BerlinAges 18 years+ - NCT07661966Recruiting
Bright light therapy for melanoma or lung cancer patients starting immunotherapy
This study tests if daily bright light therapy can help people with advanced melanoma or lung cancer feel better during their first immunotherapy treatment. The light box is used at home for a short time each morning.
New York, New YorkAges 18 years+ - NCT06240143RecruitingPhase 1/Phase 2
Intradermal immunotherapy for high-risk stage II melanoma
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
AmsterdamAges 18 years+ - NCT07644897RecruitingPhase 2
Thymosin Alpha 1 Plus Anti-PD-1 for Advanced Melanoma in Older Adults
This trial tests a combination of two drugs—thymosin alpha 1 (an immune-boosting protein) and an anti-PD-1 antibody (a cancer immunotherapy)—in patients 60 and older with advanced melanoma that cannot be surgically removed. The goal is to help the immune system fight the cancer more effectively.
Guangzhou, GuangdongAges 60 years+ - NCT07635732Recruiting
Urine Bacteria as a Test for Melanoma Treatment Response
This study looks at bacteria naturally found in urine to see if they can help diagnose melanoma and predict how well systemic therapy (medicine that spreads throughout the body) will work. Researchers believe the types of bacteria in your urine may reflect how your immune system is responding to melanoma treatment.
Gratwein, StyriaAges 18 years+ - NCT07634380RecruitingPhase 1
Sitagliptin Plus Pembrolizumab for Advanced Kidney or Skin Cancer
This study tests whether adding sitagliptin (a diabetes medication) to pembrolizumab (an immunotherapy) can help patients with advanced kidney cancer or melanoma whose cancer stopped responding to previous immunotherapy treatments. The goal is to see if this combination can shrink tumors and improve survival.
Iowa City, IowaAges 18–99 - NCT06519266RecruitingPhase 3
Liver treatment with immunotherapy for uveal melanoma that spread to the liver
This trial tests whether adding a liver-directed therapy (PHP) to a combination of two immunotherapy drugs (ipilimumab and nivolumab) works better than the immunotherapy drugs alone for people whose uveal melanoma has spread to the liver.
GothenburgAges 18 years+
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for melanoma?
- Yes. Clin2 currently lists 458 recruiting melanoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a melanoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a melanoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.